Spondylometaphyseal Dysplasia, Sedaghatian Type disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

SMDS MCID: SPN362 MIFTS: 42	Spondylometaphyseal Dysplasia, Sedaghatian Type (SMDS) Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Spondylometaphyseal Dysplasia, Sedaghatian Type

MalaCards integrated aliases for Spondylometaphyseal Dysplasia, Sedaghatian Type:

Name: Spondylometaphyseal Dysplasia, Sedaghatian Type ⁵⁷ ⁵⁸ ⁷² ³⁶ ²⁹ ⁶ ⁷⁰

Sedaghatian Chondrodysplasia ⁵⁷ ⁷²

Smds ⁵⁷ ⁷²

Metaphyseal Chondrodysplasia, Congenital Lethal ⁵⁷

Spondylometaphyseal Dysplasia Sedaghatian Type ²⁰

Congenital Lethal Metaphyseal Chondrodysplasia ⁷²

Lethal Metaphyseal Dysplasia ²⁰

Characteristics:

Orphanet epidemiological data:

⁵⁸

spondylometaphyseal dysplasia, sedaghatian type
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Antenatal,Neonatal; Age of death: infantile,stillbirth;

OMIM®:

⁵⁷ (Updated 05-Apr-2021)

Inheritance:
autosomal recessive

Miscellaneous:
death in perinatal period

HPO:

³¹

spondylometaphyseal dysplasia, sedaghatian type:
Inheritance autosomal recessive inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Fetal diseases
Anatomical: Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Congenital malformations, deformations and chromosomal abnormalities

Congenital malformations and deformations of the musculoskeletal system

Osteochondrodysplasia with defects of growth of tubular bones and spine

Other osteochondrodysplasia with defects of growth of tubular bones and spine

Orphanet: ⁵⁸

Rare bone diseases

Developmental anomalies during embryogenesis

External Ids:

OMIM® ⁵⁷ 250220

OMIM Phenotypic Series ⁵⁷ PS184255

KEGG ³⁶ H01825

MeSH ⁴⁴ D010009

MESH via Orphanet ⁴⁵ C535798

ICD10 via Orphanet ³³ Q77.8

UMLS via Orphanet ⁷¹ C1855229

Orphanet ⁵⁸ ORPHA93317

MedGen ⁴¹ C1855229

UMLS ⁷⁰ C1855229

Sources

Summaries for Spondylometaphyseal Dysplasia, Sedaghatian Type

GARD : ²⁰ The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 93317 Definition Spondylometaphyseal dysplasia (SEMD), Sedaghatian type is a neonatal lethal form of spondylometaphyseal dysplasia characterized by severe metaphyseal chondrodysplasia, mild rhizomelic shortness of the upper limbs, and mild platyspondyly. Epidemiology Nine cases have been reported so far in patients of Iranian, Yemeni and Caucasian origin. Clinical description A lacy appearance of the iliac crests, long fibulae, abnormal tarsal bones, cardiac arrhythmia, and intracranial anomalies have been described. Intrauterine growth is normal. The majority of patients die in the first days of life with symptoms of cardiorespiratory insufficiency. Subacute myocarditis, cortical necrosis of kidneys, adrenal and pulmonary hemorrhage, absence of the corpus callosum and marked frontotemporal pachygyria have been found at autopsy. Etiology Etiology remains unknown. Genetic counseling Autosomal recessive inheritance has been suggested.

MalaCards based summary : Spondylometaphyseal Dysplasia, Sedaghatian Type, also known as sedaghatian chondrodysplasia, is related to opsismodysplasia and spondylometaphyseal dysplasia with cone-rod dystrophy. An important gene associated with Spondylometaphyseal Dysplasia, Sedaghatian Type is GPX4 (Glutathione Peroxidase 4). The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and breast, and related phenotypes are delayed skeletal maturation and atrioventricular block

OMIM® : ⁵⁷ Sedaghatian-type spondylometaphyseal dysplasia (SMDS) is a rare lethal disorder characterized by severe metaphyseal chondrodysplasia with mild limb shortening, platyspondyly, delayed epiphyseal ossification, irregular iliac crests, and pulmonary hemorrhage. Affected infants present with severe hypotonia and cardiorespiratory problems; most die within days of birth due to respiratory failure. Cardiac abnormalities include conduction defects, complete heart block, and structural anomalies. Half of infants with SMDS are reported to have central nervous system malformations consistent with abnormal neuronal migration, including agenesis of the corpus callosum, pronounced frontotemporal pachygyria, simplified gyral pattern, partial lissencephaly, and severe cerebellar hypoplasia (summary by Smith et al., 2014). (250220) (Updated 05-Apr-2021)

KEGG : ³⁶ Sedaghatian type spondylometaphyseal dysplasia (SMDS) is a rare type of lethal congenital severe spondylometaphyseal dysplasia characterised by severe metaphyseal chondrodysplasia with mild limb shortening, platyspondyly, delayed epiphyseal ossification, irregular iliac crests, and pulmonary haemorrhage. Most of the patients had been reported to have a short life span, and died shortly after birth due to respiratory failure. Half of infants with SMDS are reported to have central nervous system (CNS) malformations consistent with abnormal neuronal migration, including agenesis of the corpus callosum, pronounced frontotemporal pachygyria, simplified gyral pattern, partial lissencephaly, and severe cerebellar hypoplasia. It has been reported that recessive truncating mutations in the GPX4 gene are the cause of SMDS.

UniProtKB/Swiss-Prot : ⁷² Spondylometaphyseal dysplasia, Sedaghatian type: A form of spondylometaphyseal dysplasia, a group of short stature disorders distinguished by abnormalities in the vertebrae and the metaphyses of the tubular bones. SMDS is a neonatal lethal form characterized by severe metaphyseal chondrodysplasia with mild limb shortening, platyspondyly, cardiac conduction defects, and central nervous system abnormalities.

Sources

Related Diseases for Spondylometaphyseal Dysplasia, Sedaghatian Type

Diseases related to Spondylometaphyseal Dysplasia, Sedaghatian Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)

#	Related Disease	Score
1	opsismodysplasia	11.3
2	spondylometaphyseal dysplasia with cone-rod dystrophy	11.1
3	spondyloepimetaphyseal dysplasia, strudwick type	10.6
4	cardiac arrhythmia	10.4
5	autosomal recessive disease	10.2
6	myocarditis	10.2
7	isolated oxycephaly	10.2
8	metaphyseal dysplasia	10.2
9	microphthalmia	10.2
10	leukemia, acute myeloid	10.0
11	myelodysplastic syndrome	10.0
12	lymphoma, hodgkin, classic	9.9
13	lymphoma, non-hodgkin, familial	9.9
14	coronary heart disease 1	9.9
15	aplastic anemia	9.9
16	pulmonary fibrosis and/or bone marrow failure, telomere-related, 2	9.9
17	deficiency anemia	9.9
18	myeloid leukemia	9.9
19	chromosomal triplication	9.9

Graphical network of the top 20 diseases related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

Sources

Symptoms & Phenotypes for Spondylometaphyseal Dysplasia, Sedaghatian Type

Human phenotypes related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

⁵⁸ ³¹ (show top 50) (show all 55)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	delayed skeletal maturation ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002750
2	atrioventricular block ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0001678
3	arrhythmia ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0011675
4	abnormality of the ribs ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000772
5	platyspondyly ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0000926
6	short metacarpal ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0010049
7	short palm ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0004279
8	long fibula ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0003085
9	metaphyseal chondrodysplasia ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0005871
10	spondylometaphyseal dysplasia ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0002657
11	rhizomelic arm shortening ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0004991
12	cardiorespiratory arrest ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0006543
13	iliac crest serration ⁵⁸ ³¹	hallmark (90%)	Very frequent (99-80%)	HP:0008786
14	abnormal scapula morphology ³¹	hallmark (90%)		HP:0000782
15	turricephaly ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000262
16	narrow chest ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0000774
17	cerebellar hypoplasia ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001321
18	generalized hypotonia ⁵⁸ ³¹	frequent (33%)	Frequent (79-30%)	HP:0001290
19	agenesis of corpus callosum ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0001274
20	myocarditis ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0012819
21	accelerated skeletal maturation ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0005616
22	pachygyria ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0001302
23	cone-shaped epiphysis ⁵⁸ ³¹	occasional (7.5%)	Occasional (29-5%)	HP:0010579
24	short neck ³¹			HP:0000470
25	respiratory insufficiency ⁵⁸		Frequent (79-30%)
26	depressed nasal bridge ³¹			HP:0005280
27	atrial septal defect ³¹			HP:0001631
28	short toe ³¹			HP:0001831
29	talipes equinovarus ³¹			HP:0001762
30	brachydactyly ³¹			HP:0001156
31	redundant skin ³¹			HP:0001582
32	short finger ³¹			HP:0009381
33	disproportionate short stature ⁵⁸		Very frequent (99-80%)
34	posteriorly rotated ears ³¹			HP:0000358
35	cone-shaped epiphyses of the phalanges of the hand ³¹			HP:0010230
36	rhizomelia ³¹			HP:0008905
37	short phalanx of finger ³¹			HP:0009803
38	large posterior fontanelle ³¹			HP:0004491
39	11 pairs of ribs ³¹			HP:0000878
40	short long bone ³¹			HP:0003026
41	flared iliac wings ³¹			HP:0002869
42	cone-shaped metacarpal epiphyses ³¹			HP:0006059
43	short ribs ³¹			HP:0000773
44	flat acetabular roof ³¹			HP:0003180
45	abnormality of the scapula ⁵⁸		Very frequent (99-80%)
46	metaphyseal cupping ³¹			HP:0003021
47	metaphyseal irregularity ³¹			HP:0003025
48	cupped ribs ³¹			HP:0000887
49	delayed epiphyseal ossification ³¹			HP:0002663
50	porencephalic cyst ³¹			HP:0002132

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 05-Apr-2021)

Head And Neck Neck:
short neck

Cardiovascular Heart:
atrial septal defect
cardiac arrhythmia
subacute myocarditis

Skeletal Feet:
brachydactyly
irregular tarsal bones
clubfeet

Head And Neck Head:
turricephaly
large posterior fontanel

Neurologic Central Nervous System:
porencephaly
hypotonia
focal lissencephaly

Skeletal Pelvis:
flared iliac wings
horizontal acetabular roof
small sacrosciatic notches
irregular lacy iliac crest
medial and lateral spur
more

Skeletal:
spondylometaphyseal dysplasia

Growth Height:
short stature, disproportionate

Skeletal Skull:
disproportionately small occipital bone

Head And Neck Nose:
depressed nasal bridge
flat nasal bridge

Skeletal Hands:
brachydactyly
short metacarpals
short phalanges
phalangeal cone-shaped epiphyses
metacarpal cone-shaped epiphyses

Skeletal Spine:
platyspondyly

Head And Neck Ears:
posteriorly rotated ears

Chest Ribs Sternum Clavicles And Scapulae:
11 pairs of ribs
short ribs
cupped ribs
irregular scapulae

Skeletal Limbs:
metaphyseal cupping
delayed epiphyseal ossification
irregular metaphyses
short long bones (rhizomelic shortening)
disproportionately long fibulae

Growth Weight:
normal birth weight

Chest External Features:
small, narrow chest

Skin Nails Hair Skin:
redundant skin folds

Clinical features from OMIM®:

250220 (Updated 05-Apr-2021)

Sources

Drugs & Therapeutics for Spondylometaphyseal Dysplasia, Sedaghatian Type

Drugs for Spondylometaphyseal Dysplasia, Sedaghatian Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Synonyms:

(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole

1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole

1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole

1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole

1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole

1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole

1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole

1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole

1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole

1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole

22832-87-7 (NITRATE)

22916-47-8

75319-47-0

AB00053500

AC1L1HM1

Aflorix(nitrate)

AKOS001574474

Albistat(nitrate)

Andergin(nitrate)

BPBio1_000279

BRD-A82396632-001-03-0

BRD-A82396632-008-02-7

Brentan

BRN 0965511

BSPBio_000253

BSPBio_002033

CCRIS 7924

CHEBI:6923

CHEMBL91

CID4189

Conofite(nitrate)

CPD-4501

D00416

Dactarin

Daktarin IV

DB01110

DivK1c_000156

EINECS 245-324-5

Epi-Monistat(nitrate)

Esteve brand OF miconazole

Femizol-M

Florid(nitrate)

Gyno-Daktar(nitrate)

HMS1568M15

HMS2090B21

I14-14342

IDI1_000156

imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)

Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)

Janssen cilag brand OF miconazole

Janssen-cilag brand OF miconazole

Johnston and johnston brand OF miconazole nitrate

KBio1_000156

KBio2_001445

KBio2_004013

KBio2_006581

KBio3_001533

KBioGR_000581

KBioSS_001445

Lotrimin AF(nitrate)

LS-78378

MCZ

Micantin (nitrate)

Miconasil nitrate

Miconasil Nitrate

Miconazol

Miconazol [INN-Spanish]

miconazole

Miconazole

Miconazole (JP15/USP/INN)

Miconazole [USAN:BAN:INN:JAN]

Miconazole 3

Miconazole 3 Combination Pack

Miconazole 7 Combination Pack

Miconazole esteve brand

Miconazole janssen-cilag brand

Miconazole nitrate

Miconazole nitrate salt

Miconazole-7

Miconazolo

Miconazolo [DCIT]

Miconazolum

Miconazolum [INN-Latin]

Micozole

Minostate

MJR 1762

MLS002222203

MolPort-002-557-553

Monazole 7

Monista (nitrate)

Monistat

Monistat (TN)

Monistat 1 Combination Pack

Monistat 3 Dual-Pak

Monistat 3 Vaginal Ovules

Monistat 5 Tampon

Monistat 7 Dual-Pak

Monistat 7 Vaginal Suppositories

Monistat Dual- PAK

Monistat IV

Monistat iv (TN)

Monistat-Derm

NCI60_001353

NCI60_001380

NINDS_000156

Nitrate, miconasil

Nitrate, miconazole

Novo-Miconazole Vaginal Ovules

NSC 170986

NSC169434

NSC170986

Oprea1_091955

Prestwick_335

Prestwick0_000067

Prestwick1_000067

Prestwick2_000067

Prestwick3_000067

R 18134

R-14,889

SMR001307249

SPBio_000976

SPBio_002174

Spectrum_000965

Spectrum2_001048

Spectrum3_000507

Spectrum4_000061

Spectrum5_001297

STK834405

STOCK1S-93556

UNII-7NNO0D7S5M

Vusion

Zimycan

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Synonyms:

(Chlorotrityl)imidazole

1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole

1-(a-(2-Chlorophenyl)benzhydryl)imidazole

1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole

1-(O-Chloro-a,a-diphenylbenzyl)imidazole

1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole

1-(o-Chlorotrityl)imidazole

1-(O-Chlorotrityl)imidazole

1-(o-Chloro-α,α-diphenylbenzyl)imidazole

1-(O-Chloro-α,α-diphenylbenzyl)imidazole

1-(α-(2-Chlorophenyl)benzhydryl)imidazole

1-(Α-(2-chlorophenyl)benzhydryl)imidazole

117829-71-7

23593-75-1

33894_FLUKA

33894_RIEDEL

3ACDFDF8-38E3-4368-85D0-BDF8AE1E6591

AB00051951

AC1L1EIW

AC-279

B 5097

BAY 5097

Bay b 5097

BAY b 5097

Bay b 9057

BAY b5097

BAY-5097

Bay-B 5097

BAYb 5097

Bayer brand 1 OF clotrimazole

Bayer Brand 1 of Clotrimazole

Bayer brand 2 OF clotrimazole

Bayer Brand 2 of Clotrimazole

BIDD:GT0450

BIDD:PXR0036

Bio-0442

BPBio1_000126

BRN 0622318

BSPBio_000114

BSPBio_002057

C 6019

C06922

C22H17ClN2

C6019_SIGMA

Canesten

Canesten 1-day cream combi-pak

Canesten 1-Day Cream Combi-Pak

Canesten 1-day therapy

Canesten 1-Day Therapy

Canesten 3-day therapy

Canesten 3-Day Therapy

Canesten 6-day therapy

Canesten 6-Day Therapy

Canesten combi-pak 1-day therapy

Canesten Combi-Pak 1-Day Therapy

Canesten combi-pak 3-day therapy

Canesten Combi-Pak 3-Day Therapy

Canesten cream

Canesten Cream

Canesten solution

Canesten Solution

Canestene

Canestine

Canifug

CAS-23593-75-1

CCRIS 6245

CHEBI:3764

CHEMBL104

Chlotrimazole

CID2812

Cimitidine

Clomatin

Clotrimaderm

Clotrimaderm cream

Clotrimazol

Clotrimazol [INN-Spanish]

clotrimazole

Clotrimazole

Clotrimazole (JP15/USP/INN)

Clotrimazole [USAN:INN:BAN:JAN]

Clotrimazole schering brand

Clotrimazole Schering Brand

Clotrimazolum

Clotrimazolum [INN-Latin]

clotrimeizol

CPD000058306

CPD-8926

Cutistad

D00282

D003022

DB00257

Desamix F

DivK1c_000665

DRG-0072

EINECS 245-764-8

Empecid

Esparol

EU-0100315

FB 5097

FB b 5097

Fem care

Fem Care

FemCare

Gino-Lotremine

Gyne lotrimin

Gyne-lotrimin

Gyne-Lotrimin

Gyne-lotrimin 3

Gyne-Lotrimin 3

Gyne-lotrimin 3 combination pack

Gyne-Lotrimin 3 Combination Pack

Gyne-lotrimin combination pack

Gyne-Lotrimin Combination Pack

Gyne-lotrimin3

Gyne-lotrimin3 combination pack

Gynix

HMS1568F16

HMS1920O21

HMS2051E11

HMS2091G10

HMS502B07

HSDB 3266

I01-3474

IDI1_000665

Kanesten

KBio1_000665

KBio2_001823

KBio2_004391

KBio2_006959

KBio3_001277

KBioGR_000850

KBioSS_001823

Klotrimazole

Lopac0_000315

Lopac-C-6019

Lotrimax

Lotrimin

Lotrimin (TN)

Lotrimin af

Lotrimin Af

Lotrimin af cream

Lotrimin AF Cream

Lotrimin af jock-itch cream

Lotrimin AF Jock-Itch Cream

Lotrimin af lotion

Lotrimin AF Lotion

Lotrimin af solution

Lotrimin AF Solution

Lotrimin cream

Lotrimin Cream

Lotrimin lotion

Lotrimin Lotion

Lotrimin solution

Lotrimin Solution

Lotrisone

LS-78271

MLS000028502

MLS000758243

MLS001423972

MolPort-002-557-756

mono-Baycuten

Monobaycuten

Mono-baycuten

Mycelax

Mycelex

Mycelex (TN)

Mycelex 7

Mycelex cream

Mycelex Cream

Mycelex g

Mycelex G

Mycelex otc

Mycelex OTC

Mycelex solution

Mycelex Solution

Mycelex troches

Mycelex Troches

Mycelex twin pack

Mycelex Twin Pack

Mycelex: mycosporinrimazole

Mycelex: MycosporinRimazole

Mycelex-7

Mycelex-7 combination pack

Mycelex-7 Combination Pack

Mycelex-g

Mycelex-G

Myclo cream

Myclo Cream

Myclo solution

Myclo Solution

Myclo spray solution

Myclo Spray Solution

Myclo-gyne

Myclo-Gyne

Mycofug

Mycosporin

Mykosporin

Nalbix

NCGC00015251-01

NCGC00015251-02

NCGC00015251-03

NCGC00015251-09

NCGC00093761-01

NCGC00093761-02

NCGC00093761-03

NCGC00093761-04

NCGC00093761-05

NCGC00093761-06

nchembio.65-comp9

nchembio790-comp30

NCIMech_000609

Neo-zol cream

Neo-Zol Cream

NINDS_000665

NSC 257473

NSC257473

Otomax

Pan-Fungex

Pedisafe

Prestwick_120

Prestwick0_000267

Prestwick1_000267

Prestwick2_000267

Prestwick3_000267

QTL1_000024

Rimazole

S1606_Selleck

SAM001247056

Schering brand OF clotrimazole

Schering Brand of Clotrimazole

SMR000058306

SPBio_000176

SPBio_002333

Spectrum_001343

SPECTRUM1500200

Spectrum2_000128

Spectrum3_000359

Spectrum4_000295

Spectrum5_000781

Stiemazol

STK700023

Tibatin

Trimysten

Trivagizole 3

UNII-G07GZ97H65

Veltrim

ZINC03807804

Immunosuppressive Agents

Phase 4

Immunologic Factors

Phase 4

Anti-Infective Agents

Phase 4

Cyclosporins

Phase 4

Antirheumatic Agents

Phase 4

Dermatologic Agents

Phase 4

Antilymphocyte Serum

Phase 4

Antifungal Agents

Phase 4

Calcineurin Inhibitors

Phase 4

Thiamine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 3

70-16-6, 59-43-8

1130

Synonyms:

[5-[[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium-3-yl]methyl]-2-methylpyrimidin-4-yl]azanium dichloride

100660-17-1

115461-66-0

1sbr

2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol

2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazol-3-ium-5-yl]ethanol chloride

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydrox yethyl)-4-methylthiazolium chloride

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethylthiazolium chloride, monohydrochloride

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methylthiazolium chloride monohydrochloride

3-(4-AMINO-2-methyl-pyrimidin-5-ylmethyl)-5-(2-hydroxy-ethyl)-4-methyl-thiazol-3-ium

3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM

3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride

3[(4-Amino-2-methyl-5-pyrimidinyl)-methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride

3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium

3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride

3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride hydrochloride

55463-15-5

57777-32-9

59-43-8

67-03-8

AC-11683

AC1L1ASK

AC1L1LOC

AC1LAODT

AC1Q4V9Q

AI3-18993

AKOS000668650

Aneurin

Aneurine

Antiberiberi factor

Apatate drape

Apate drops

AR-1L8201

B-Amin

BAS 00266240

Beatine

Bedome

Begiolan

Beivon

Benerva

Bequin

Berin

Betabion

Betalin S

Betaxin

Bethiamin

Bethiazine

Beuion

Bevitex

Bevitine

Bewon

Biamine

Bithiamin

Biuno

Bivatin

Bivita

bmse000274

BPBio1_000686

BSPBio_000622

C00378

C12H17N4OS

CCRIS 1906

CCRIS 5823

Cernevit-12

CHEBI:18385

CHEBI:33283

CHEBI:49105

CHEMBL1547

CHEMBL1588

Chloride-hydrochloride salt of thiamine

CID1130

CID517305

CID6042

Clotiamina

D08580

DB00152

EINECS 200-425-3

EINECS 200-641-8

Eskapen

Eskaphen

FEMA No. 3322

HSDB 220

Hybee

I14-14339

Lixa-beta

LS-3226

LT00233141

Metabolin

MLS001304099

MolPort-000-722-048

MolPort-001-920-086

MolPort-002-052-059

Mononitrate, thiamine

nchembio.121-comp5

NChemBio.2007.13-comp10

NSC 36226

NSC36226

Oryzanin

Oryzanine

Prestwick0_000631

Prestwick1_000631

Prestwick2_000631

Prestwick3_000631

SBB058094

Slowten

SMP1_000084

SMR000718788

SPBio_002841

ST095175

THD

Thiadoxine

thiamin

Thiamin

Thiamin dichloride

THIAMIN, VITAMIN B1

Thiaminal

thiamine

Thiamine

Thiamine (INN)

Thiamine [INN:BAN]

Thiamine chloride

Thiamine chloride hydrochloride

Thiamine dichloride

Thiamine HCL

Thiamine hydrochloride [JAN]

Thiamine monochloride

Thiamine monohydrochloride

Thiamine mononitrate

thiamine(1+)

thiamine(1+) ion

Thiamine(1+) ion

Thiamine, chloride

Thiamine, chloride, hydrochloride

Thiamine, monohydrochloride

thiaminium

Thiaminium

Thiaminium chloride hydrochloride

Thiaminum

Thiaminum [INN-Latin]

Thiamol

Thiavit

Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-m- ethyl, chloride, monohydrochloride

Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride

Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl- chloride (1:1)

Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-, chloride, monohydrochloride

Thiazolium, 3-((4-amino-2-methyl-5-pyrimidinyl)methyl)-5-(2-hydroxyethyl)-4-methyl-chloride

Tiamidon

Tiamina

Tiamina [INN-Spanish]

Tiaminal

TimTec1_000613

Trophite

UNII-X66NSO3N35

Vetalin S

VIB

Vinothiam

Vitamin b 1

vitamin B1

Vitamin b1

Vitamin B1

Vitamin B1 (TN)

Vitamin B1 hydrochloride (VAN)

vitamin b1(thiamine)

Vitaneurin

Vitaneuron

ZINC00049153

Vitamins

Phase 3

Vitamin B Complex

Phase 3

Thiamin

Phase 3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Synonyms:

(3H)-Dexamethasone

.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol

.gamma.corten

137098-19-2

16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol

16.alpha.-Methyl-9.alpha.-fluoroprednisolone

16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol

16alpha -Methyl-9alpha -fluoroprednisolone

16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol

16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol

16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone

16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone

16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone

16alpha-Methyl-9alpha-fluoroprednisolone

16-alpha-Methyl-9-alpha-fluoroprednisolone

16a-Methyl-9a-fluoro-1-dehydrocortisol

16α-Methyl-9α-fluoro-1-dehydrocortisol

16Α-methyl-9α-fluoro-1-dehydrocortisol

1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone

1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone

1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone

1-Dehydro-16a-methyl-9a-fluorohydrocortisone

1-Dehydro-16α-methyl-9α-fluorohydrocortisone

23495-06-9

31375_FLUKA

46165_FLUKA

46165_RIEDEL

50-02-2

8054-59-9

9.alpha.-Fluoro-16.alpha.-methylprednisolone

906422-84-2

9a-Fluoro-16a-methylprednisolone

9a-Fluoro-16BETA-methylprednisolone

9A-FLUORO-16BETA-METHYLPREDNISOLONE

9alpha -Fluoro-16alpha -methylprednisolone

9alpha-Fluoro-16alpha-methylprednisolone

9alpha-Fluoro-16alpha-methyl-prednisolone

9-alpha-Fluoro-16-alpha-methylprednisolone

9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione

9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione

9-Fluoro-16-methylprednisolone

9α-Fluoro-16α-methylprednisolone

9Α-fluoro-16α-methylprednisolone

AC-11056

AC1L1L1H

AC1Q29DM

Adexone

Aeroseb-D

Aeroseb-dex

Aeroseb-Dex

AI3-50934

Ak dex OPH otic soln 0.1%

Alcon brand OF dexamethasone

Alcon Brand of Dexamethasone

alpha -Fluoro-16-alpha -methylcortisol

Anaflogistico

Aphtasolon

Aphthasolone

Apo-dexamethasone

Auxiron

Azimycin (veterinary)

Azium

Azium (veterinary)

Azium (Veterinary)

BIDD:ER0494

BIDD:PXR0060

Bisu Ds

Bisu DS

BRD-K38775274-001-02-3

BRD-K38775274-001-06-4

BSPBio_000995

C15643

C22H29FO5

Calonat

CCRIS 7067

CHEBI:41879

CHEMBL384467

CID5743

Corson

Corsone

Cortisumman

CPD001227192

CPD-10549

D00292

D003907

D1756_SIGMA

D4902_SIGMA

D6645_SIGMA

D8893_SIGMA

D9184_SIGMA

DB01234

Decacort

Decacortin

Decaderm

Decadron

Decadron (TN)

Decadron Tablets, Elixir

Decadron, Dexamethasone

Decadron-La

Decadron-LA

Decagel

Decaject

Decaject l.a.

Decaject L.A.

Decaject-l.a.

Decaject-L.A.

Decalix

Decameth

Decasone

Decaspray

Dectancyl

Dekacort

delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol

delta1-9alpha-Fluoro-16alpha-methylcortisol

Delta1-9alpha-Fluoro-16alpha-methylcortisol

Deltafluorene

Dergramin

Deronil

Desadrene

Desametasone

Desametasone [Dcit]

Desametasone [DCIT]

Desamethasone

Desameton

Deseronil

DEX

Dexa

DEXA

Dexa mamallet

Dexa Mamallet

Dexacen-4

Dexacidin

Dexacort

Dexacortal

Dexa-cortidelt

Dexa-Cortidelt

Dexacortin

Dexa-cortisyl

Dexa-Cortisyl

Dexadeltone

Dexafarma

Dexair

Dexalona

Dexaltin

Dexa-Mamallet

Dexametasona

Dexametasona [INN-Spanish]

Dexametasone

Dexameth

Dexamethansone

dexamethasone

Dexamethasone

Dexaméthasone

Dexamethasone (JP15/USP/INN)

Dexamethasone [INN:BAN:JAN]

Dexamethasone acetate

Dexamethasone Acetate

Dexamethasone alcohol

Dexamethasone Alcohol

Dexamethasone base

Dexamethasone Base

Dexamethasone intensol

Dexamethasone Intensol

Dexamethasone sodium phosphate

Dexamethasone Sodium Phosphate

Dexamethasone-omega

Dexamethasonum

Dexamethasonum [INN-Latin]

Dexamethazone

Dexamonozon

Dexapolcort

Dexapos

Dexaprol

Dexa-scheroson

Dexa-Scheroson

Dexa-sine

Dexa-Sine

Dexason

Dexasone

Dexasone 0.5MG

Dexasone 0.75MG

Dexasone 4MG

Dexasporin

Dex-ide

Dex-Ide

Dexinolon

Dexinoral

Dexone

Dexone 0.5

DEXONE 0.5

Dexone 0.75

DEXONE 0.75

Dexone 1.5

DEXONE 1.5

Dexone 4

DEXONE 4

Dexonium

Dexpak

Dextelan

Dezone

Dinormon

DXM

Dxms

DXMS

ECR brand OF dexamethasone

ECR Brand of Dexamethasone

EINECS 200-003-9

Fluormethylprednisolone

Fluormone

Fluorocort

Fortecortin

Foy brand OF dexamethasone

Foy Brand of Dexamethasone

FT-0080377

Gammacorten

Hexadecadrol

Hexadrol

Hexadrol elixir

Hexadrol Elixir

Hexadrol Tablets

Hl-dex

Hl-Dex

HL-Dex

HMS1792A17

HMS1990A17

HMS2089N13

HSDB 3053

I06-1196

ICN brand OF dexamethasone

ICN Brand of Dexamethasone

IontoDex

Isopto-dex

Isopto-Dex

Lokalison F

Loverine

LS-7300

Luxazone

Maxidex

Maxidex ont 0.1%

Maxidex sus 0.1%

Maxitrol

Mediamethasone

Merck brand OF dexamethasone

Merck Brand of Dexamethasone

Merz brand 1 OF dexamethasone

Merz Brand 1 of Dexamethasone

Merz brand 2 OF dexamethasone

Merz Brand 2 of Dexamethasone

Methylfluorprednisolone

Mexidex

Millicorten

MK 125

MLS001055412

MLS001332507

MLS001332508

MolMap_000018

MolPort-003-846-433

Mymethasone

Naquasone (veterinary)

NCGC00091019-01

NCGC00091019-02

NCGC00091019-03

NCGC00091019-04

NCGC00091019-05

nchembio809-comp2

NCI60_003067

Neomycin and polymyxin b sulfates and dexamethasone

Neomycin and polymyxin b sulphates and dexamethasone

NSC 34521

NSC34521

Ocu-trol

Ocu-Trol

Oradexon

OTO-104

Pet derm III

Pet Derm Iii

Pet Derm III

Pet-Derm Iii

PHL-Dexamethasone

PMS Dexamethasone elixir 0.5mg/5ML

PMS-Dexamethasone

Policort

Posurdex

Prednisolon F

Prednisolone F

Prodex

S1322_Selleck

SAM002548948

Sandoz dexamethasone

SGCUT00126

Sk-Dexamethasone

SK-Dexamethasone

SMP1_000092

SMR000857119

SMR001227192

Spectrum5_002019

Spoloven

ST50307091

Sunia sol D

Sunia Sol D

Superprednol

TL8003317

to_000038

Tobradex

Tobramycin and dexamethasone

Tresaderm (veterinary)

Turbinaire

UNII-7S5I7G3JQL

Visumetazone

WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1

ZINC03875332

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DFDC

2',2'-DiF-dC

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate

2'-Deoxy-2'-difluorocytidine

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFdC

DFDC

DFdCyd

Folfugem

Gamcitabine

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

gemcitabine

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer

Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Gemcitabine, (D-threo-pentafuranosyl)-isomer

Gemcitabinum

Gemcitabinum [INN-Latin]

GemLip

Gemtro

Gemzar

Gemzar (hydrochloride)

GEO

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY188011

LY-188011

NCGC00168784-01

NChemBio.2007.10-comp25

nchembio.573-comp7

nchembio.90-comp2

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

Zefei

ZINC18279854

Decitabine

Approved, Investigational

Phase 1, Phase 2

2353-33-5

451668

Synonyms:

2' Deoxy 5 azacytidine

2353-33-5

2'-Deoxy-5-azacytidine

4-Amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one

4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one

4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one

4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one

4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one

5 Aza 2' deoxycytidine

5 Azadeoxycytidine

5 Deoxyazacytidine

5A2dc

5-Aza-2&prime

5-aza-2'-deoxycytidine

5-aza-2-deoxycytidine

5-Aza-2'-deoxycytidine

5-aza-CdR

5-aza-dC

5AzadC

5-AzadC

5-AZAdC

5-azadeoxycytidine

5-Azadeoxycytidine

5-Deoxy-2&prime

5-Deoxyazacytidine

A3656_SIGMA

AC-1135

AC1L9PS9

-azacytidine

Azadc

AzadC

AzadC compound

CHEBI:50131

CHEMBL1201129

CID451668

Compound, azadc

D03665

DAC

Dacogen

Dacogen (TN)

Dacogen, 5-aza-2'-deoxycytidine,NSC 127716, Dacogen, DAC, Decitabine

DB01262

Decitabina

Decitabine

Decitabine (USAN/INN)

Decitabine mesylate

-Deoxycytidine

Dezocitidine

E-7373

FT-0082622

Mesylate, decitabine

MLS001332587

MLS001332588

MolMap_000063

NCGC_5ADOC

NSC127716

NSC-127716

S1200_Selleck

SBB066121

SMR000857076

TL8001944

Azacitidine

Approved, Investigational

Phase 1, Phase 2

320-67-2

9444

Synonyms:

2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one

320-67-2

4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one

4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz

4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one

4-Amino-1-b-D-ribofuranosyl-S-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one

4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one

4-amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one

4-Amino-1-beta-D-ribofuranosyl-S-triazin-2(1H)-one

4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one

4-Amino-1-β-D-ribofuranosyl-S-triazin-2(1H)-one

5 Azacytidine

5 AZC

5-AC

5AzaC

5-AZAC

5-azacitidine

5-aza-CR

5-azacytidine

5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine

5-AZCR

A 2385

A1287_SIGMA

A2385_SIGMA

AC1L1T1Y

Antibiotic U 18496

Azacitidina

Azacitidina [INN-Spanish]

Azacitidine

Azacitidine (JAN/USAN/INN)

Azacitidine [USAN:INN]

Azacitidinum

Azacitidinum [INN-Latin]

Azacytidine

BCBcMAP01_000083

BRN 0620461

BSPBio_003157

C11262

CCRIS 60

CHEBI:2038

CHEMBL1489

CID9444

cMAP_000082

CPD000857239

D001374

D03021

DB00928

DivK1c_000125

EINECS 206-280-2

EU-0100035

FT-0081170

HMS1921J22

HMS2092D08

HMS500G07

HSDB 6879

IDI1_000125

InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1

Jsp005945

KBio1_000125

KBio2_001742

KBio2_002556

KBio2_004310

KBio2_005124

KBio2_006878

KBio2_007692

KBio3_002657

KBio3_003034

KBioGR_001444

KBioGR_002556

KBioSS_001742

KBioSS_002565

Ladakamycin

Lopac0_000035

LS-1189

MLS001333121

MLS001333122

MLS002153249

MolMap_000062

mylo sar

Mylosar

NCGC00090851-01

NCGC00090851-02

NCGC00090851-03

NCGC00090851-04

NCGC00090851-08

NCGC00178234-01

NCI-C01569

NINDS_000125

NS-17

NSC 102816

NSC102816

NSC-102816

Pharmion brand OF azacitidine

Pharmion Brand of Azacitidine

pyrimidine antimetabolite: inhibits nucleic acid replication

S1782_Selleck

SAM002264595

SMR000857239

SPBio_000892

Spectrum_001262

SPECTRUM1502111

Spectrum2_000786

Spectrum3_001509

Spectrum4_000922

Spectrum5_001166

ST056940

s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI)

TL80073599

U 18496

U-18496

UNII-M801H13NRU

Vidaza

Vidaza (TN)

wr 183027

WR-183027

ZINC03861768

Gastrointestinal Agents

Phase 2

Hormone Antagonists

Phase 2

glucocorticoids

Phase 2

Antiemetics

Phase 2

Hormones

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Anti-Inflammatory Agents

Phase 2

Alkylating Agents

Phase 2

Antiviral Agents

Phase 2

Antimetabolites

Phase 2

Bendamustine Hydrochloride

Phase 2

Anesthetics

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome	Completed	NCT00488436	Phase 4	Antithymocyte globulin;Cyclosporine
2	Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Colorectal Cancer Resection: a Randomized Clinical Trial	Completed	NCT02813278	Phase 3
3	A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Completed	NCT01469832	Phase 1, Phase 2
4	A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Completed	NCT01345006	Phase 1, Phase 2
5	The Efficacy of Bendamustine, Gemcytabine, Dexamethasone (BGD) Salvage Chemotherapy With Autologous Stem Cell Transplantation (ASCT) Consolidation in Advanced Classical Hodgkin Lymphoma Patients Not Responding to ABVD Therapy- Multicentre Phase II Clinical Study (PLRG-HL1/BURGUND)	Recruiting	NCT03615664	Phase 2	Bendamustine;Gemcitabine;Dexamethasone
6	A Phase I-II Trial of Acadesine in IPSS High and Int-2 SMD, LAM With 20-30% Marrow Blasts and CMML Type 2 Not Responding to Azacitidine or Decitabine for at Least 6 Courses or Relapsing After a Response	Terminated	NCT01813838	Phase 1, Phase 2	ACADESINE 140mg/kg/d;ACADESINE 210mg/kg/d;ACADESINE 315mg/kg/d
7	A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)	Unknown status	NCT01625559	Phase 1
8	Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence	Completed	NCT01770691
9	Follow-up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Completed	NCT02941991
10	Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Completed	NCT02445612
11	Sternomental Displacement and Neck Circumference as Predictors of Difficult Airway in Obese Patients During General Anesthesia: a Prospective Observational Cohort Study	Not yet recruiting	NCT04524546
12	To Evaluate the Performance of a Urine Spermine Measuring Device in Predicting Prostate Biopsy Result	Not yet recruiting	NCT04339920

Search NIH Clinical Center for Spondylometaphyseal Dysplasia, Sedaghatian Type

Sources

Genetic Tests for Spondylometaphyseal Dysplasia, Sedaghatian Type

Genetic tests related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

#	Genetic test	Affiliating Genes
1	Spondylometaphyseal Dysplasia, Sedaghatian Type ²⁹	GPX4

Sources

Anatomical Context for Spondylometaphyseal Dysplasia, Sedaghatian Type

MalaCards organs/tissues related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

⁴⁰

Bone, Brain, Breast, Prostate, Heart, Ovary, Lung

Sources

Publications for Spondylometaphyseal Dysplasia, Sedaghatian Type

Articles related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

(show top 50) (show all 1163)

#	Title	Authors	PMID	Year
1	Mutations in the enzyme glutathione peroxidase 4 cause Sedaghatian-type spondylometaphyseal dysplasia. ⁵⁷ ⁶	Smith AC...Graham GE	24706940	2014
2	Simplified gyral pattern with cerebellar hypoplasia in Sedaghatian type spondylometaphyseal dysplasia: a clinical report and review of the literature. ⁵⁷ ⁶	Aygun C...Incesu L	22529034	2012
3	Spondylometaphyseal dysplasia: Sedaghatian type. ⁶¹ ⁵⁷	Koutouby A...Moinuddin FA	10678656	2000
4	Spondylometaphyseal dysplasia-Sedaghatian type. ⁶¹ ⁵⁷	Elcioglu N...Hall CM	9556300	1998
5	Spondylometaphyseal dysplasia, Sedaghatian type. ⁵⁷ ⁶¹	Peeden JN...Gruber HE	1481828	1992
6	Sedaghatian spondylometaphyseal dysplasia with pachygyria and absence of the corpus callosum. ⁵⁷	English SJ...Crow YJ	16892303	2006
7	Sedaghatian congenital lethal metaphyseal chondrodysplasia--observations in a second Iranian family and histopathological studies. ⁵⁷	Opitz JM...Azadeh B	3565474	1987
8	Congenital lethal metaphyseal chondrodysplasia: a newly recognized complex autosomal recessive disorder. ⁵⁷	Sedaghatian MR	7211944	1980
9	Non-pharmacological treatment for Parkinson disease patients with depression: a meta-analysis of repetitive transcranial magnetic stimulation and cognitive-behavioral treatment. ⁶¹	Chen J...Wang L	32253965	2021
10	Effects of Resistance Training Performed to Failure or Not to Failure on Muscle Strength, Hypertrophy, and Power Output: A Systematic Review With Meta-Analysis. ⁶¹	Vieira AF...Cadore EL	33555822	2021
11	Neutrophil and Neutrophil-to-Lymphocyte Ratio as Clinically Predictive Risk Markers for Recurrent Pregnancy Loss. ⁶¹	Jiang S...Zhao X	33237515	2021
12	Supervised Multidimensional Scaling and its Application in MRI-Based Individual Age Predictions. ⁶¹	Cao X...Tian L	32676970	2021
13	Markers of endothelial dysfunction and arterial stiffness in patients with early-stage autosomal dominant polycystic kidney disease: A meta-analysis. ⁶¹	Bellos I...Perrea DN	32946652	2021
14	Differential role of melatonin in healthy brain aging: a systematic review and meta-analysis of the SAMP8 model. ⁶¹	Sumsuzzman DM...Hong Y	33811754	2021
15	Patients' perspectives on a new delivery model in primary care: A propensity score matched analysis of patient-reported outcomes in a Dutch cohort study. ⁶¹	van den Bogaart EHA...Ruwaard D	32701197	2021
16	Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis. ⁶¹	Sayour AA...Radovits T	33483761	2021
17	The use of acupuncture for advanced cancer care: Protocol for a systematic review and meta-analysis. ⁶¹	Jiang Z...Chen Z	33426711	2021
18	Changes in aqueous and vitreous inflammatory cytokine levels in neovascular age-related macular degeneration: a systematic review and meta-analysis. ⁶¹	Minaker SA...Muni RH	32602185	2021
19	Patient preference and clinical working time between digital scanning and conventional impression making for implant-supported prostheses: A systematic review and meta-analysis. ⁶¹	Manicone PF...D'addona A	33678434	2021
20	Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis. ⁶¹	Zou Q...Shi H	33771065	2021
21	Health wearable devices for weight and BMI reduction in individuals with overweight/obesity and chronic comorbidities: systematic review and network meta-analysis. ⁶¹	McDonough DJ...Gao Z	33731385	2021
22	Movement disorders in primary central nervous system lymphoma: two unreported cases and a review of literature. ⁶¹	Grillo P...Schirinzi T	33443666	2021
23	Anti-inflammatory effects of melatonin: A systematic review and meta-analysis of clinical trials. ⁶¹	Cho JH...Irwin MR	33581247	2021
24	Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis. ⁶¹	Bignamini AA...Matuska J	33502688	2021
25	Responsiveness of kinematic and clinical measures of upper-limb motor function after stroke: A systematic review and meta-analysis. ⁶¹	Villepinte C...Gasq D	32156646	2021
26	How does anterior cruciate ligament reconstruction affect the functioning of the brain and spinal cord? A systematic review with meta-analysis. ⁶¹	Rodriguez KM...Krishnan C	32707098	2021
27	Evaluation of post-adolescence exposure to bisphenol A on reproductive outcomes of male rodent models. ⁶¹	Ren X...Wang S	33757772	2021
28	Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis. ⁶¹	Bahji A...Vazquez G	33174452	2021
29	Effects of antibiotic administration on post-operative endodontic symptoms in patients with pulpal necrosis: A systematic review and meta-analysis. ⁶¹	Shamszadeh S...Eghbal MJ	32681652	2021
30	Play and medical play in teaching pre-school children to cope with medical procedures involving needles: A systematic review. ⁶¹	Kyriakidis I...Magos K	33710698	2021
31	Drugging the "undruggable" microRNAs. ⁶¹	Liu D...Zha W	33052435	2021
32	Role of Arts Therapy in Patients with Breast and Gynecological Cancers: A Systematic Review and Meta-Analysis. ⁶¹	Cheng P...Zhu J	33507828	2021
33	Oral administration of mangiferin ameliorates diabetes in animal models: a meta-analysis and systematic review. ⁶¹	Wu Y...Liu T	33601215	2021
34	Childhood trauma and cardiometabolic risk in severe mental disorders: The mediating role of cognitive control. ⁶¹	Lunding SH...Steen NE	33775258	2021
35	Nonpharmacological Interventions for Pediatric Migraine: A Network Meta-analysis. ⁶¹	Koechlin H...Locher C	33688031	2021
36	Neurocognitive Effects of Chemotherapy for Colorectal Cancer: A Systematic Review and a Meta-Analysis of 11 Studies. ⁶¹	Hwang SY...Jung SJ	33735557	2021
37	Immediate and long-term effects of mechanical loading on Achilles tendon volume: A systematic review and meta-analysis. ⁶¹	Merza E...Malliaras P	33556887	2021
38	Effects of Whole Grain Intake, Compared with Refined Grain, on Appetite and Energy Intake: A Systematic Review and Meta-Analysis. ⁶¹	Sanders LM...Maki KC	33530093	2021
39	Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta-analysis. ⁶¹	Shang W...Han D	33146450	2021
40	Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. ⁶¹	Tong J...Li Q	33523319	2021
41	Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials. ⁶¹	Marchi M...Galeazzi GM	33538213	2021
42	Platelet-rich plasma injection vs corticosteroid injection for conservative treatment of rotator cuff lesions: A protocol for systematic review and meta-analysis. ⁶¹	Wang C...Zhu Q	33607808	2021
43	Exercise Interventions for Persistent Non-Specific Low Back Pain - Does Matching Outcomes to Treatment Targets Make a Difference? A Systematic Review and Meta-Analysis. ⁶¹	Wood L...Bishop A	32580060	2021
44	Helicobacter pylori infection is associated with a poor response to levodopa in patients with Parkinson's disease: a systematic review and meta-analysis. ⁶¹	Zhong R...Lin W	33616741	2021
45	Efficacy and safety of blood purification in the treatment of deep burns: A systematic review and meta-analysis. ⁶¹	Zhang G...Luo H	33592850	2021
46	Chemokines in post-traumatic stress disorder: A network meta-analysis. ⁶¹	Pan X...Liu A	33242653	2021
47	Comparative efficacy and acceptability of expressive writing treatments compared with psychotherapy, other writing treatments, and waiting list control for adult trauma survivors: a systematic review and network meta-analysis. ⁶¹	Gerger H...Cuijpers P	33634766	2021
48	Dynamic contrast-enhanced MRI of synovitis in knee osteoarthritis: repeatability, discrimination and sensitivity to change in a prospective experimental study. ⁶¹	MacKay JW...Parker GJM	33591383	2021
49	The prognostic effects of hemodynamic parameters on rupture of intracranial aneurysm: A systematic review and meta-analysis. ⁶¹	Han P...Li X	33444872	2021
50	Preventing Staphylococcus aureus stainless steel-associated infections in orthopedics. A systematic review and meta-analysis of animal literature. ⁶¹	Tsikopoulos K...Lavalette D	33527485	2021

Sources

Genes for Spondylometaphyseal Dysplasia, Sedaghatian Type

Genes related to Spondylometaphyseal Dysplasia, Sedaghatian Type (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	GPX4	Glutathione Peroxidase 4	Protein Coding	1367.67	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative germline mutation ⁵⁸ Genetic Tests ²⁹ GeneCards inferred via : Disorders Variants (show sections)	24706940

Sources

Variations for Spondylometaphyseal Dysplasia, Sedaghatian Type

ClinVar genetic disease variations for Spondylometaphyseal Dysplasia, Sedaghatian Type:

⁶

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	GPX4	NM_002085.5(GPX4):c.476+5G>A	SNV	Pathogenic	140615	rs775146234	GRCh37: 19:1105813-1105813 GRCh38: 19:1105814-1105814
2	GPX4	NM_002085.5(GPX4):c.477-8_477-4del	Deletion	Pathogenic	140616	rs1599810980	GRCh37: 19:1106230-1106234 GRCh38: 19:1106231-1106235
3	GPX4	NM_002085.5(GPX4):c.270C>A (p.Tyr90Ter)	SNV	Pathogenic	140617	rs769967246	GRCh37: 19:1105455-1105455 GRCh38: 19:1105456-1105456
4	GPX4	NM_002085.5(GPX4):c.85-321G>A	SNV	Uncertain significance	1028980		GRCh37: 19:1104864-1104864 GRCh38: 19:1104865-1104865

Sources

Expression for Spondylometaphyseal Dysplasia, Sedaghatian Type

Search GEO for disease gene expression data for Spondylometaphyseal Dysplasia, Sedaghatian Type.

Sources

Pathways for Spondylometaphyseal Dysplasia, Sedaghatian Type

Sources

GO Terms for Spondylometaphyseal Dysplasia, Sedaghatian Type

Sources

Sources for Spondylometaphyseal Dysplasia, Sedaghatian Type

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia

Spondylometaphyseal Dysplasia, Sedaghatian Type (SMDS)

Aliases & Classifications for Spondylometaphyseal Dysplasia, Sedaghatian Type

MalaCards integrated aliases for Spondylometaphyseal Dysplasia, Sedaghatian Type:

Characteristics:

Orphanet epidemiological data:

OMIM®:

HPO:

Classifications:

External Ids:

Summaries for Spondylometaphyseal Dysplasia, Sedaghatian Type

Related Diseases for Spondylometaphyseal Dysplasia, Sedaghatian Type

Diseases related to Spondylometaphyseal Dysplasia, Sedaghatian Type via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

Symptoms & Phenotypes for Spondylometaphyseal Dysplasia, Sedaghatian Type

Human phenotypes related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

Symptoms via clinical synopsis from OMIM®:

Clinical features from OMIM®:

Drugs & Therapeutics for Spondylometaphyseal Dysplasia, Sedaghatian Type

Drugs for Spondylometaphyseal Dysplasia, Sedaghatian Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Spondylometaphyseal Dysplasia, Sedaghatian Type

Genetic tests related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

Anatomical Context for Spondylometaphyseal Dysplasia, Sedaghatian Type

MalaCards organs/tissues related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

Publications for Spondylometaphyseal Dysplasia, Sedaghatian Type

Articles related to Spondylometaphyseal Dysplasia, Sedaghatian Type:

Genes for Spondylometaphyseal Dysplasia, Sedaghatian Type

Genes related to Spondylometaphyseal Dysplasia, Sedaghatian Type (1 elite genes):

Variations for Spondylometaphyseal Dysplasia, Sedaghatian Type

ClinVar genetic disease variations for Spondylometaphyseal Dysplasia, Sedaghatian Type:

Expression for Spondylometaphyseal Dysplasia, Sedaghatian Type

Pathways for Spondylometaphyseal Dysplasia, Sedaghatian Type

GO Terms for Spondylometaphyseal Dysplasia, Sedaghatian Type

Sources for Spondylometaphyseal Dysplasia, Sedaghatian Type